Abstracts tagged "inflammation and signal transduction"

Abstract Number: 983 • 2018 ACR/ARHP Annual Meeting
A MAPK Activated Kinase 2 Inhibitor Attenuates Inflammatory and Destructive Arthritis in Human Ex Vivo Models
Tue Wenzel Kragstrup^1,2, Anders Mellemkjær³, Morten Aagaard Nielsen⁴, Line Dam Heftdal², Marie Iversen³, Peter Schafer⁵ and Bent Deleuran², ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark, ⁴Of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Celgene Corporation, Summit, NJ
Background/Purpose: Targeting intracellular pathways with oral small molecules is an attractive therapeutic approach for treating immune mediated inflammatory diseases. The mitogen-activated protein kinase (MAPK) pathway…
Abstract Number: 1599 • 2012 ACR/ARHP Annual Meeting
NF-Kb Inducing Kinase (NIK) Is a Key Regulator of Inflammation-Induced Angiogenesis
A.R. Noort¹, K.P.M. van Zoest¹, P. Koolwijk², D.V. Novack³, M.J. Siemerink⁴, P. P. Tak⁵ and S.W. Tas⁶, ¹Division of Clinical Immunology & Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Physiology, Institute for Cardiovascular Research (ICaR-VU) / VU University Medical Center, Amsterdam, Netherlands, ³Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, MO, ⁴Department of Ophthalmology and Department of Cell Biology and Histology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands, ⁶Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: In rheumatoid arthritis (RA) synovial tissue (ST) angiogenesis can be observed already in the earliest phase of disease, which may be critical in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].